Investors see Biogen CEO choice as friendly to potential takeover

NEW YORK (Reuters) - The surprise selection of Michel Vounatsos to run Biogen Inc signals a shift toward a more commercial management focus after years of targeting ambitious scientific gains, and likely keeps the U.S. biotech in play as a takeover target.

Investors see Biogen CEO choice as friendly to potential takeover
Read More


Bagikan Berita Ini